US EditionPublished • loading... • Updated
Pfizer Shares Drop on Quarterly Loss
Pfizer cited a $4.4 billion asset impairment and a 35% drop in Covid-19 vaccine sales as key factors in its $1.6 billion loss and lower 2026 revenue forecast.
- On 03/02/2026, Pfizer reported a quarterly loss of $410 million and confirmed lower 2026 revenue guidance of $59.5 to $62.5 billion, said Pfizer.
- Pressure from upcoming generic competition included a $1.5 billion revenue hit in 2026, a $4.4 billion asset impairment, and Covid-19 declines; Bourla said `2026` will be important.
- Pfizer outlined 20 planned trials in 2026, half for Metsera obesity assets, with Bourla saying it "will be an important year rich in key catalysts," while Eliquis sales grew.
- Shares dropped 3.2 percent in morning trading after Pfizer said `Current financial guidance does not anticipate any share repurchases in 2026` while funding R&D and reducing debt.
- Looking ahead, Pfizer is prioritizing R&D spending in 2026 with a guidance of $10.5 to $11.5 billion, relying on Seagen and Metsera acquisitions, while Chris Boshoff called anti-obesity results `encouraging` and targets approvals in 2028.
Insights by Ground AI
18 Articles
18 Articles
ABC FOX Montana+13 Reposted by 13 other sources
Pfizer shares drop on quarterly loss
Pfizer reported a quarterly loss Tuesday following a large write-down, denting shares as it confirmed 2026 financial targets with lower revenues.
·Missoula, United States
Read Full Article
In the fourth quarter, losses of 1,397 million euros were recorded against atypical profits ...
·Luxembourg City, Luxembourg
Read Full Article
One cancer drug steps back, and obesity asset steps forward, as Pfizer reports earnings
Pfizer took a write-down on one of its recent high-profile acquisitions while reporting a positive readout from another. The pharma giant said on Tuesday it took a $4.4 billion impairment charge related in part to ...
Coverage Details
Total News Sources18
Leaning Left1Leaning Right2Center5Last UpdatedBias Distribution62% Center
Bias Distribution
- 62% of the sources are Center
62% Center
13%
C 62%
R 25%
Factuality
To view factuality data please Upgrade to Premium
